{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:37:57Z","timestamp":1787017077294,"version":"build-2736575974"},"reference-count":63,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec id=\"s1\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To summarise radiographic data in randomised controlled trials (RCTs) as part of the radiographic inhibition claim of disease-modifying antirheumatic drugs (DMARDs) approved for patients with rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"s2\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systemic literature review was performed using the Medline database from 1994 to February 2020. The results were grouped based on the scoring methods (Sharp, Genant modification, van der Heijde modification) and RA patient populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"s3\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred sixty-eight publications were selected. After detailed assessment, 52 RCTs (7 methotrexate (MTX)-naive, 23 MTX inadequate response (IR), 9 DMARDs IR and 3 tumour necrosis factor-alpha inhibitors (TNFi) IR studies) were finally included. Information on patient population, scoring method used, reader reliability, statistical analyses and detailed radiographic data on baseline and change scores over multiple follow-up periods are presented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"s4\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The data gathered in this review serve as a repository for the design of future trials with radiographic damage as an outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001277","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T11:32:47Z","timestamp":1594812767000},"page":"e001277","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct01521923","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00791921","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7346-0820","authenticated-orcid":false,"given":"Yune-Jung","family":"Park","sequence":"first","affiliation":[{"name":"Internal Medicine, The Catholic University of Korea, Seoul, Korea (the Republic of)"},{"name":"Rheumatology, St. Vincent\u2019s Hospital, The Catholic University of Korea, Suwon, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Gherghe","sequence":"additional","affiliation":[{"name":"Internal Medicine and Rheumatology, Cantacuzino Hospital, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"Desir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Rheumatology, LUMC, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"2025090312305372000_6.2.e001277.1","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"2025090312305372000_6.2.e001277.2","unstructured":"Smolen JS , Landewe RBM , Bijlsma JWJ , et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;annrheumdis-2019-216655."},{"key":"2025090312305372000_6.2.e001277.3","unstructured":"Services USDoHaH, Administration FaD, (CDER) CfDEaR , et al. Guidance for industry clinical development programs for drugs, devices, and biological products for the treatment of Rheumatoid Arthritis (RA). Available https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-development-programs-drugs-devices-and-biological-products-treatment-rheumatoid-arthritis"},{"key":"2025090312305372000_6.2.e001277.4","unstructured":"(CHMP) CfMPfHU . Guideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis. Available https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-rheumatoid-arthritis_en.pdf"},{"key":"2025090312305372000_6.2.e001277.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203159"},{"key":"2025090312305372000_6.2.e001277.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.146043"},{"key":"2025090312305372000_6.2.e001277.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.10683"},{"key":"2025090312305372000_6.2.e001277.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7023.71"},{"key":"2025090312305372000_6.2.e001277.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2025090312305372000_6.2.e001277.10","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"2010","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025090312305372000_6.2.e001277.11","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U"},{"key":"2025090312305372000_6.2.e001277.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432201"},{"key":"2025090312305372000_6.2.e001277.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.20568"},{"key":"2025090312305372000_6.2.e001277.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.21519"},{"key":"2025090312305372000_6.2.e001277.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61000-4"},{"key":"2025090312305372000_6.2.e001277.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.30263"},{"key":"2025090312305372000_6.2.e001277.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137703"},{"key":"2025090312305372000_6.2.e001277.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201247"},{"key":"2025090312305372000_6.2.e001277.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101121"},{"key":"2025090312305372000_6.2.e001277.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202433"},{"key":"2025090312305372000_6.2.e001277.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207628"},{"key":"2025090312305372000_6.2.e001277.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316133"},{"key":"2025090312305372000_6.2.e001277.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"2025090312305372000_6.2.e001277.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207511"},{"key":"2025090312305372000_6.2.e001277.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209057"},{"key":"2025090312305372000_6.2.e001277.26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheum"},{"key":"2025090312305372000_6.2.e001277.27","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P"},{"key":"2025090312305372000_6.2.e001277.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05246-0"},{"key":"2025090312305372000_6.2.e001277.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"},{"key":"2025090312305372000_6.2.e001277.30","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-12-200606200-00003"},{"key":"2025090312305372000_6.2.e001277.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.30158"},{"key":"2025090312305372000_6.2.e001277.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.23964"},{"key":"2025090312305372000_6.2.e001277.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101659"},{"key":"2025090312305372000_6.2.e001277.34","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099010"},{"key":"2025090312305372000_6.2.e001277.35","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.116319"},{"key":"2025090312305372000_6.2.e001277.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.200317"},{"key":"2025090312305372000_6.2.e001277.37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev338"},{"key":"2025090312305372000_6.2.e001277.38","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3109\/14397595.2013.843764","article-title":"Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial","volume":"24","author":"Yamamoto","year":"2014","journal-title":"Mod Rheum"},{"key":"2025090312305372000_6.2.e001277.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201282"},{"key":"2025090312305372000_6.2.e001277.40","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"2025090312305372000_6.2.e001277.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201411"},{"key":"2025090312305372000_6.2.e001277.42","doi-asserted-by":"publisher","DOI":"10.1002\/art.37711"},{"key":"2025090312305372000_6.2.e001277.43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208052"},{"key":"2025090312305372000_6.2.e001277.44","doi-asserted-by":"crossref","unstructured":"Yoo DH , Racewicz A , Brzezicki J , et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther 2016;18:82.","DOI":"10.1186\/s13075-016-0981-6"},{"key":"2025090312305372000_6.2.e001277.45","doi-asserted-by":"publisher","DOI":"10.1002\/art.39093"},{"key":"2025090312305372000_6.2.e001277.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"2025090312305372000_6.2.e001277.47","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/rheumatology\/kex269","article-title":"52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis","volume":"56","author":"Emery","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312305372000_6.2.e001277.48","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/rheumatology\/kex254","article-title":"Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results","volume":"56","author":"Smolen","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312305372000_6.2.e001277.49","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215164"},{"key":"2025090312305372000_6.2.e001277.50","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a Phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheum"},{"key":"2025090312305372000_6.2.e001277.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"2025090312305372000_6.2.e001277.52","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068064"},{"key":"2025090312305372000_6.2.e001277.53","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201796"},{"key":"2025090312305372000_6.2.e001277.54","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3109\/14397595.2013.865822","article-title":"Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study","volume":"24","author":"Tanaka","year":"2014","journal-title":"Mod Rheum"},{"key":"2025090312305372000_6.2.e001277.55","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3109\/s10165-012-0742-6","article-title":"A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis","volume":"23","author":"Takeuchi","year":"2013","journal-title":"Mod Rheum"},{"key":"2025090312305372000_6.2.e001277.56","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/acr.22384","article-title":"Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"66","author":"Kivitz","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312305372000_6.2.e001277.57","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211328"},{"key":"2025090312305372000_6.2.e001277.58","first-page":"88","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"64","author":"Dougados","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025090312305372000_6.2.e001277.59","first-page":"216","article-title":"Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies","volume":"64","author":"Keystone","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025090312305372000_6.2.e001277.60","doi-asserted-by":"crossref","unstructured":"Chatzidionysiou K , Turesson C , Teleman A , et al. A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open 2016;2:e000133.","DOI":"10.1136\/rmdopen-2015-000133"},{"key":"2025090312305372000_6.2.e001277.61","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40744-017-0086-y","article-title":"Secukinumab in active rheumatoid arthritis after anti-TNF\u03b1 therapy: a randomized, double-blind Placebo-controlled Phase 3 Study","volume":"4","author":"Tahir","year":"2017","journal-title":"Rheum Ther"},{"key":"2025090312305372000_6.2.e001277.62","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018457"},{"key":"2025090312305372000_6.2.e001277.63","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/acr.22426","article-title":"Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis","volume":"67","author":"Landewe","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:31:05Z","timestamp":1756927865000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":63,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,7,15]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/rmdopen-2020-001277"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001277","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}